Decades after Raphael Mechoulam linked CBD with treating epilepsy, his latest finding may help develop new drugs for psoriasis, arthritis and anxiety.

The U.S. government will spend $3 million to find out if marijuana can relieve pain, but none of the money will be used to study the part of the plant that gets people high.

Researchers accidentally proved that marijuana has the potential to ease the pain of capsaicin, which is the chemical responsible for putting the “hot” in hot peppers.

Chocolate can throw off potency tests so labels aren’t always accurate, and now scientists are trying to figure out why.

Arizona-based researcher Dr. Sue Sisley is spearheading an extraordinary lawsuit against the U.S. Drug Enforcement Administration (DEA), demanding that the agency stop dragging its feet on a years-old promise to end the federal government’s monopoly on growing cannabis for clinical research.

“The findings demonstrate the potential for this new cannabis derivative in the treatment of both localized and advanced pancreatic cancer,” the study’s authors wrote. “The results justify further studies to optimize therapy outcomes toward clinical translation.”

Researchers at the University of California, Davis, have partnered with a federally compliant pharmaceutical company to analyze the chemical and biological profiles of cannabis for the benefit of law enforcement, health care providers and scientific professionals.

CBDV, or cannabidivarin, is one of many molecules derived from cannabis and hemp plants.

CBN –an abbreviation of Cannabinol– comes from the oxidation and decomposition of THC from a hemp plant, meaning that when THC is heated and exposed to Co2 (oxygen), it converts to CBN.